A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

被引：0
|
作者：
Ye, Ding-Wei
Gu, Weijie
Han, Weiqing
Luo, Hong
Zhou, Fangjian
He, Dalin
Ma, Lulin
Guo, Hongqian
Liang, Chaozhao
Chong, Tie
Jiang, Jun
Chen, Zhiwen
Wang, Yong
Zou, Qing
Tian, Ye
Xiao, Jun
Huang, Jian
Yang, Xinfeng
Li, Junliang
Jin, Chunlei
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Ctr, Changsha, Peoples R China
[3] Chongqing Univ, Canc Hosp, Chongqing Canc Hosp, Chongqing, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[5] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China
[6] Peking Univ Third Hosp, Beijing, Peoples R China
[7] Nanjing Drum Tower Hosp, Nanjing, Peoples R China
[8] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China
[9] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Peoples R China
[10] Army Med Univ, Daping Hosp, Chongqing, Peoples R China
[11] Army Med Univ, Southwest Hosp, Chongqing, Peoples R China
[12] Tianjin Med Univ, Hosp 2, Tianjin, Peoples R China
[13] Jiangsu Canc Hosp, Nanjing, Peoples R China
[14] Capital Med Univ, Beijing Friendly Hosp, Beijing, Peoples R China
[15] USTC, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China
[16] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[17] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
[18] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5003
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
    Gu, Weijie
    Han, Weiqing
    Luo, Hong
    Zhou, Fangjian
    He, Dalin
    Ma, Lulin
    Guo, Hongqian
    Liang, Chaozhao
    Chong, Tie
    Jiang, Jun
    Chen, Zhiwen
    Wang, Yong
    Zou, Qing
    Tian, Ye
    Xiao, Jun
    Huang, Jian
    Zhu, Shaoxing
    Dong, Qiang
    Zhang, Xiaoping
    Li, Hanzhong
    Yang, Xinfeng
    Chen, Chunxia
    Li, Junliang
    Jin, Chunlei
    Zhang, Xiaojing
    Ye, Dingwei
    LANCET ONCOLOGY, 2022, 23 (10): : 1249 - 1260
  • [2] Patient-reported outcomes (PROs) for rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): An analysis of the CHART randomized, open-label, phase 3 trial.
    Ye, Ding-Wei
    Jiang, Shusuan
    Luo, Hong
    Zhou, Fangjian
    He, Dalin
    Ma, Lulin
    Guo, Hongqian
    Liang, Chaozhao
    Chong, Tie
    Jiang, Jun
    Chen, Zhiwen
    Wang, Yong
    Zou, Qing
    Tian, Ye
    Xiao, Jun
    Huang, Jian
    Chen, Jinchao
    Yang, Xinfeng
    Lian, Jianpo
    Wang, Wenliang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study
    Wang, Hongkai
    Jiang, Shusuan
    Luo, Hong
    Zhou, Fangjian
    He, Dalin
    Ma, Lulin
    Guo, Hongqian
    Liang, Chaozhao
    Chong, Tie
    Jiang, Jun
    Chen, Zhiwen
    Wang, Yong
    Zou, Qing
    Tian, Ye
    Xiao, Jun
    Huang, Jian
    Chen, Jinchao
    Dong, Qiang
    Zhang, Xiaoping
    Li, Hanzhong
    Yang, Xinfeng
    Lian, Jianpo
    Wang, Wenliang
    Ye, Dingwei
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [4] Randomized trial of androgen deprivation therapy (ADT) plus enzalutamide (Arm A) versus ADT plus bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)
    Vaishampayan, U. N.
    Heilbrun, L.
    Monk, P.
    Sonpavde, G.
    Tejwani, S.
    Heath, E. I.
    Fontana, J.
    Chinni, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Phase 3 Study of Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) or Placebo (PBO) in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): The Arches Trial
    Horvath, Lisa
    Armstrong, Andrew J.
    Szmulewitz, Russell
    Petrylak, Daniel
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Stenzl, Arnulf
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 32 - 33
  • [6] Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
    Takashi Ueda
    Takumi Shiraishi
    Masatsugu Miyashita
    Naruhiro Kayukawa
    Yusuke Gabata
    Satoshi Sako
    Ryota Ogura
    Atsuko Fujihara
    Koji Okihara
    Osamu Ukimura
    Scientific Reports, 14
  • [7] Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
    Ueda, Takashi
    Shiraishi, Takumi
    Miyashita, Masatsugu
    Kayukawa, Naruhiro
    Gabata, Yusuke
    Sako, Satoshi
    Ogura, Ryota
    Fujihara, Atsuko
    Okihara, Koji
    Ukimura, Osamu
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [8] KEYNOTE-991: PHASE 3 STUDY OF PEMBROLIZUMAB PLUS ENZALUTAMIDE AND ANDROGEN DEPRIVATION THERAPY (ADT) FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
    Gratzke, Christian
    Gratzke, Christian
    Gratzke, Christian
    Niu, Cuizhen
    Poehlein, Christian
    Burgents, Joseph
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A211 - A211
  • [9] Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial
    Saad, F.
    Vjaters, E.
    Shore, N. D.
    Olmos, D.
    Xing, N.
    Gomes, A. J. P. D. S.
    Mota, A. C. A.
    Salman, P.
    Jievaltas, M.
    Ulys, A.
    Jakubovskis, M.
    Kopyltsov, E.
    Han, W.
    Nevalaita, L.
    Testa, I.
    Le Berre, M-A.
    Kuss, I.
    Kunhiparambath, H.
    ANNALS OF ONCOLOGY, 2024, 35 : 1257 - 1258
  • [10] ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Holzbeierlein, Jeffrey M.
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris Yakovlevich
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Baron, Benoit
    Chen, Lucy F.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345